Research ExplorerPublicationsThe effect of age on cancer-specific mortality in patients w...

The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages

Standard

The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. / Knipper, Sophie; Pecoraro, Angela; Palumbo, Carlotta; Rosiello, Giuseppe; Luzzago, Stefano; Deuker, Marina; Tian, Zhe; Shariat, Shahrokh F; Saad, Fred; Tilki, Derya; Graefen, Markus; Karakiewicz, Pierre I.

In: CANCER CAUSE CONTROL, Vol. 31, No. 3, 03.2020, p. 283-290.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Knipper, S, Pecoraro, A, Palumbo, C, Rosiello, G, Luzzago, S, Deuker, M, Tian, Z, Shariat, SF, Saad, F, Tilki, D, Graefen, M & Karakiewicz, PI 2020, 'The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages', CANCER CAUSE CONTROL, vol. 31, no. 3, pp. 283-290. https://doi.org/10.1007/s10552-020-01273-5

APA

Knipper, S., Pecoraro, A., Palumbo, C., Rosiello, G., Luzzago, S., Deuker, M., Tian, Z., Shariat, S. F., Saad, F., Tilki, D., Graefen, M., & Karakiewicz, P. I. (2020). The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. CANCER CAUSE CONTROL, 31(3), 283-290. https://doi.org/10.1007/s10552-020-01273-5

Vancouver

Knipper S, Pecoraro A, Palumbo C, Rosiello G, Luzzago S, Deuker M et al. The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. CANCER CAUSE CONTROL. 2020 Mar;31(3):283-290. https://doi.org/10.1007/s10552-020-01273-5

Bibtex

@article{95a2ffcdec874efe997e9c3fe95a5d0d,
title = "The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages",
abstract = "PURPOSE: To test the effect of age on cancer-specific mortality (CSM) in most contemporary prostate cancer (PCa) patients of all stages and across all treatment modalities.METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 579,369 PCa patients. Cumulative incidence plots and multivariable competing-risks regression analyses (MCR) were used. Subgroup analyses were performed according to ethnicity (African-Americans), clinical stage (T1-2N0M0, T3-4N0M0, TanyN1M0, and TanyNanyM1), as well as treatment modalities.RESULTS: Patient distribution was as follows: 142,338 (24.6%) < 60 years; 113,064 (19.5%) 60-64 years; 127,158 (21.9%) 65-69 years; 94,782 (16.4%) 70-74 years; and 102,027 (17.6%) ≥ 75 years. Older patients harbored worse tumor characteristics and more frequently received no local treatment. Overall, 10-year CSM rates were 4.8, 5.3, 5.9, 7.6, and 14.6%, respectively, in patients aged < 60, 60-64, 65-69, 70-74 ,and ≥ 75 years (p < 0.001). In MCR focusing on the overall cohort and T1-2N0M0 patients, older age independently predicted higher CSM, but not in T3-4N0-1M0-1 patients.CONCLUSIONS: Older age was associated with higher grade and stage and independently predicted higher CSM in T1-2N0M0 patients, but not in higher stages. Differences in diagnostics and therapeutics seem to affect elderly patients within T1-2N0M0 PCa and should be avoided if possible.",
author = "Sophie Knipper and Angela Pecoraro and Carlotta Palumbo and Giuseppe Rosiello and Stefano Luzzago and Marina Deuker and Zhe Tian and Shariat, {Shahrokh F} and Fred Saad and Derya Tilki and Markus Graefen and Karakiewicz, {Pierre I}",
year = "2020",
month = mar,
doi = "10.1007/s10552-020-01273-5",
language = "English",
volume = "31",
pages = "283--290",
journal = "CANCER CAUSE CONTROL",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "3",

}

RIS

TY - JOUR

T1 - The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages

AU - Knipper, Sophie

AU - Pecoraro, Angela

AU - Palumbo, Carlotta

AU - Rosiello, Giuseppe

AU - Luzzago, Stefano

AU - Deuker, Marina

AU - Tian, Zhe

AU - Shariat, Shahrokh F

AU - Saad, Fred

AU - Tilki, Derya

AU - Graefen, Markus

AU - Karakiewicz, Pierre I

PY - 2020/3

Y1 - 2020/3

N2 - PURPOSE: To test the effect of age on cancer-specific mortality (CSM) in most contemporary prostate cancer (PCa) patients of all stages and across all treatment modalities.METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 579,369 PCa patients. Cumulative incidence plots and multivariable competing-risks regression analyses (MCR) were used. Subgroup analyses were performed according to ethnicity (African-Americans), clinical stage (T1-2N0M0, T3-4N0M0, TanyN1M0, and TanyNanyM1), as well as treatment modalities.RESULTS: Patient distribution was as follows: 142,338 (24.6%) < 60 years; 113,064 (19.5%) 60-64 years; 127,158 (21.9%) 65-69 years; 94,782 (16.4%) 70-74 years; and 102,027 (17.6%) ≥ 75 years. Older patients harbored worse tumor characteristics and more frequently received no local treatment. Overall, 10-year CSM rates were 4.8, 5.3, 5.9, 7.6, and 14.6%, respectively, in patients aged < 60, 60-64, 65-69, 70-74 ,and ≥ 75 years (p < 0.001). In MCR focusing on the overall cohort and T1-2N0M0 patients, older age independently predicted higher CSM, but not in T3-4N0-1M0-1 patients.CONCLUSIONS: Older age was associated with higher grade and stage and independently predicted higher CSM in T1-2N0M0 patients, but not in higher stages. Differences in diagnostics and therapeutics seem to affect elderly patients within T1-2N0M0 PCa and should be avoided if possible.

AB - PURPOSE: To test the effect of age on cancer-specific mortality (CSM) in most contemporary prostate cancer (PCa) patients of all stages and across all treatment modalities.METHODS: Within the Surveillance, Epidemiology, and End Results database (2004-2016), we identified 579,369 PCa patients. Cumulative incidence plots and multivariable competing-risks regression analyses (MCR) were used. Subgroup analyses were performed according to ethnicity (African-Americans), clinical stage (T1-2N0M0, T3-4N0M0, TanyN1M0, and TanyNanyM1), as well as treatment modalities.RESULTS: Patient distribution was as follows: 142,338 (24.6%) < 60 years; 113,064 (19.5%) 60-64 years; 127,158 (21.9%) 65-69 years; 94,782 (16.4%) 70-74 years; and 102,027 (17.6%) ≥ 75 years. Older patients harbored worse tumor characteristics and more frequently received no local treatment. Overall, 10-year CSM rates were 4.8, 5.3, 5.9, 7.6, and 14.6%, respectively, in patients aged < 60, 60-64, 65-69, 70-74 ,and ≥ 75 years (p < 0.001). In MCR focusing on the overall cohort and T1-2N0M0 patients, older age independently predicted higher CSM, but not in T3-4N0-1M0-1 patients.CONCLUSIONS: Older age was associated with higher grade and stage and independently predicted higher CSM in T1-2N0M0 patients, but not in higher stages. Differences in diagnostics and therapeutics seem to affect elderly patients within T1-2N0M0 PCa and should be avoided if possible.

U2 - 10.1007/s10552-020-01273-5

DO - 10.1007/s10552-020-01273-5

M3 - SCORING: Journal article

C2 - 32034540

VL - 31

SP - 283

EP - 290

JO - CANCER CAUSE CONTROL

JF - CANCER CAUSE CONTROL

SN - 0957-5243

IS - 3

ER -